AB1121 HOW FEARS AND HOPES HAVE EVOLVED IN PATIENTS WITH RMDs THROUGHOUT THE COVID-19 PANDEMIC? RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2)

Background The COVID-19 pandemic has generated uncertainties and concerns along with expectations hopes that may be of relevance to patients rheumatic diseases. Objectives aim this study is assess changes in the fears diseases throughout two phases REUMAVID. Methods REUMAVID an international cross-sectional collecting data through online survey seven European countries led by Health & Territory Research group University Seville, together a multidisciplinary team including patient representatives, rheumatologists, health researchers. Data were collected phases: Phase 1 (P1) between April-July 2020 2 (P2) February-April 2021. Demographics, behaviours, employment status, access healthcare services, disease characteristics, WHO-5 Well-Being Index Hospital Anxiety Depression Scale (HADS). Participants rated series (infection, medication consequences, lack medication, impact on healthcare, lost job, civil disorder) scale from zero (“no concern at all”) five (“extremely concerned”) (treatment/vaccine availability, going outside, travel, economic situation, treatment continuation, status) hopeful hopeful”). Descriptive analysis Mann-Whitney test used explore both Results A total 3,802 participants recruited across comparable demographic characteristics: mean age 52.6 vs. 55.0 years (P2), 80.2% female 83.7% 69.6% married 68.3% 48.6% university educated 47.8% (P2). Most prevalent RMD was axial spondyloarthritis P1 (37.2%), rheumatoid arthritis P2 (53.1%). In major future (3.1 3.2 out 5, p=0.051). Compared P1, had less about medications not reaching country (2.4 1.9, p<0.001), disorders (2.0 1.8, p=0.001), or losing their jobs (1.4 1.5, p=0.003). Comparing greater availability treatments vaccines suitable for (3.2 3.9, able go as before 3.5, travel (2.8 3.3, maintain even improve current situation after (2.6 3.0, continue usual (3.8 3.8, p=0.049; Table 1) 1. Bivariate patients’ (N= 3,802, unless specify) Mean ± SD P-value First n= 1,800 Second phase 2,002 Fears Impact future, 3,653 3.1 1.6 0.051 Treatment taken could make you more likely get serious illness infection, 3,651 2.8 1.8 2.9 0.160 More infected due condition, 3,649 1.7 0.040 Lack 3,656 2.4 1.9 <0.001 Civil disorder, 3,634 2.0 0.001 Lost 3,566 1.5 1.4 0.003 Hopes Availability vaccine COVID-19, 3,318 3.9 1.3 <0.001* Continue usual, 3,306 3.7 3.8 0.049* Go pandemic, 3.5 Don’t same health, 3,280 0.696 Travel 3,311 3.3 Maintain 3,310 2.6 3.0 Conclusion During first beginning RMDs fearful compared second phase. These notable terms RMD, while during phase, against being before. Acknowledgements This supported Novartis Pharma AG. We would like thank all completed well organisations participated including: Cyprus League People Rheumatism (CYLPER) Cyprus, Association Française de Lutte Anti-Rhumatismale (AFLAR) France, Hellenic Against (ELEANA) Greece, Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) Italy, Portuguese Rheumatic Diseases (LPCDR), Portugal, Spanish Federation Spondyloarthritis Associations (CEADE), Patients’ Forum (FEP), UNiMiD, Rheumatology (LIRE), Andalusian (LIRA), Catalonia Galician Spain, National Axial Society (NASS), Rheumatoid Arthritis (NRAS) Action United Kingdom. Disclosure Interests Marco Garrido-Cumbrera Grant/research support from: research collaboration provides services AG, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda UCB, Consultant of: Pfizer Laura Christen Employee José Correa-Fernández: None declared, Elsa Mateus grants Lilly Sanofi, Grünenthal S.A., MSD, Medac, Janssen-Cilag, Pharmakern GAfPA, LAURENT GRANGE: Dale Webb Clare Jacklin Abbvie, Amgen, Eli Gilead, Roche, Sanofi Shantel Irwin: Serena Mingolla: KATY ANTONOPOULOU: Souzi Makri GSK Bayer, Victoria Navarro-Compán BMS, Roche UCB